TheStreet downgraded shares of Misonix (NASDAQ:MSON) from a c rating to a d+ rating in a research report released on Wednesday, TheStreetRatingsTable reports.

Separately, ValuEngine downgraded shares of Misonix from a buy rating to a hold rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and an average target price of $28.50.

NASDAQ MSON traded down $0.24 during trading hours on Wednesday, reaching $17.16. 62,012 shares of the company traded hands, compared to its average volume of 92,564. Misonix has a 12 month low of $15.21 and a 12 month high of $27.54. The company has a current ratio of 3.51, a quick ratio of 2.53 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $298.07 million, a PE ratio of -29.59 and a beta of 0.47. The company has a 50 day moving average of $18.30 and a two-hundred day moving average of $19.07.

Misonix (NASDAQ:MSON) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.08). Misonix had a negative net margin of 14.40% and a negative return on equity of 7.80%. The company had revenue of $19.72 million for the quarter.

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of Misonix by 200.6% in the 4th quarter. Bank of America Corp DE now owns 10,759 shares of the medical equipment provider’s stock worth $200,000 after buying an additional 7,180 shares during the last quarter. UBS Group AG lifted its position in shares of Misonix by 40.0% in the 4th quarter. UBS Group AG now owns 13,703 shares of the medical equipment provider’s stock worth $255,000 after buying an additional 3,913 shares during the last quarter. Parkman Healthcare Partners LLC bought a new position in shares of Misonix in the 4th quarter worth about $3,955,000. Citigroup Inc. lifted its position in shares of Misonix by 340.8% in the 4th quarter. Citigroup Inc. now owns 1,609 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 1,244 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Misonix by 121.3% in the 4th quarter. Barclays PLC now owns 8,026 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 4,399 shares during the last quarter. Institutional investors own 28.79% of the company’s stock.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Further Reading: Shanghai Stock Exchange Composite Index

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.